Literature DB >> 12193079

G-protein-coupled receptors in human atherosclerosis: comparison of vasoconstrictors (endothelin and thromboxane) with recently de-orphanized (urotensin-II, apelin and ghrelin) receptors.

Sidath D Katugampola1, Rhoda E Kuc, Janet J Maguire, Anthony P Davenport.   

Abstract

Endothelin (ET)-1 and thromboxane (Tx) levels are increased in human atherosclerosis. One of the aims of this study was to understand how receptors for a peptide mediator (ET-1) with a long physiological half life, would differ from a lipid mediator (TxA(2)), with a short physiological half life, in human coronary artery disease (CAD). Secondly, to determine if receptor protein is present in human coronary artery vascular smooth muscle for the recently adopted peptide orphan receptors for urotensin-II, apelin and ghrelin. The ET(A) receptor subtype predominated in the medial smooth muscle layer of both non-diseased coronary artery (NCA) and CAD. However, this subtype was present at relatively low density in the proliferated intimal layer of CAD. The ET(B) receptor protein was not altered with CAD, compared with NCA. Tx receptor density was significantly (P<0.05) increased in both the media and intima of CAD, compared with NCA. There was no alteration in receptor density, on the medial smooth muscle for urotensin-II and apelin with CAD. Interestingly, receptor density for the novel vasodilator peptide ghrelin was significantly (P<0.05) increased (approx. 4 fold) with CAD, compared with NCA. The alteration of receptor density with disease for Tx and ghrelin provides novel therapeutic targets for the treatment of atherosclerosis. In conclusion, while some GPCR are altered, others remain unchanged with human atherosclerosis. The increase in vasoconstrictor Tx receptor density with disease suggests the importance of Tx receptor antagonism. Intriguingly, the increase in receptor density for the novel vasodilator ghrelin, identified from post-genomic research, may potentially be beneficial with human atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12193079     DOI: 10.1042/CS103S171S

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  7 in total

1.  Adipocyte dysfunction and hypertension.

Authors:  Junlan Zhou; Gangjian Qin
Journal:  Am J Cardiovasc Dis       Date:  2012-05-15

2.  Time-resolved fluorescence ligand binding for G protein-coupled receptors.

Authors:  Alexander Emami-Nemini; Thomas Roux; Marion Leblay; Emmanuel Bourrier; Laurent Lamarque; Eric Trinquet; Martin J Lohse
Journal:  Nat Protoc       Date:  2013-06-13       Impact factor: 13.491

3.  Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis.

Authors:  Hyung J Chun; Ziad A Ali; Yoko Kojima; Ramendra K Kundu; Ahmad Y Sheikh; Rani Agrawal; Lixin Zheng; Nicholas J Leeper; Nathan E Pearl; Andrew J Patterson; Joshua P Anderson; Philip S Tsao; Michael J Lenardo; Euan A Ashley; Thomas Quertermous
Journal:  J Clin Invest       Date:  2008-10       Impact factor: 14.808

4.  Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.

Authors:  A M D Watson; M Olukman; C Koulis; Y Tu; D Samijono; D Yuen; C Lee; D J Behm; M E Cooper; K A M Jandeleit-Dahm; A C Calkin; T J Allen
Journal:  Diabetologia       Date:  2013-01-24       Impact factor: 10.122

5.  Anti-inflammatory activity of ghrelin in human carotid artery cells.

Authors:  Kevin B S Chow; Christopher H K Cheng; Helen Wise
Journal:  Inflammation       Date:  2009-12       Impact factor: 4.092

Review 6.  Pathophysiology of isoprostanes in the cardiovascular system: implications of isoprostane-mediated thromboxane A2 receptor activation.

Authors:  Jochen Bauer; Anne Ripperger; Stefan Frantz; Süleyman Ergün; Edzard Schwedhelm; Ralf A Benndorf
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

Review 7.  Ghrelin and vascular protection.

Authors:  James T Pearson; Mikiyasu Shirai; Vijayakumar Sukumaran; Cheng-Kun Du; Hirotsugu Tsuchimochi; Takashi Sonobe; Mark T Waddingham; Rajesh Katare; Daryl O Schwenke
Journal:  Vasc Biol       Date:  2019-09-05
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.